ORMP.TA - Oramed Pharmaceuticals Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in USD
1,511.00
-14.00 (-0.92%)
As of 9:55AM IST. Market open.
Stock chart is not supported by your current browser
Previous Close1,525.00
Open1,525.00
Bid1,514.00 x 0
Ask1,557.00 x 0
Day's Range1,510.00 - 1,511.00
52 Week Range1,510.00 - 1,511.00
Volume581
Avg. VolumeN/A
Market Cap266.324M
Beta (3Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.82
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Oramed working on first insulin pill for diabetes
    Yahoo Finance Video

    Oramed working on first insulin pill for diabetes

    Oramed Pharmaceuticals is waiting on approval from the FDA after its new insulin pill to treat type two diabetes had successful results in its phase two trial. Oramed Pharmaceuticals CEO Nadav Kidron joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss on The First Trade.

  • Oramed Appoints Dr. Arie Mayer to Board of Directors
    PR Newswire

    Oramed Appoints Dr. Arie Mayer to Board of Directors

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Arie Mayer, Ph.D. to its Board of Directors.

  • Oramed to Present a Scientific Poster at International Diabetes Federation Congress
    PR Newswire

    Oramed to Present a Scientific Poster at International Diabetes Federation Congress

    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabetes Federation (IDF) Congress in Busan, South Korea to be held December 2-6. Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will present the poster.

  • Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
    PR Newswire

    Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

    NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same" has been granted by the Japanese Patent Office. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
    PR Newswire

    Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2019, where a panel of investigators and Key Opinion Leaders presented detailed findings from the Company's successful Phase IIb study of ORMD-0801 in the treatment of type 2 diabetes. Panelists presenting the data included: Dr. Joel Neutel, Principal Investigator of the study and Director of Research at Orange County Research Center; Kenneth Homer, the trial's biostatistician; Dr. Ramachandra Naik, Professor of Medicine/Endocrinology at SUNY Upstate Medical University; and Dr. Alexander Fleming, CEO of Kinexum, and former Head of Clinical Review of Endocrine and Metabolic Drugs at the U.S. Food and Drug Administration (FDA).

  • Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
    PR Newswire

    Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • PR Newswire

    Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

    NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.

  • Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
    PR Newswire

    Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav Kidron, will  present and participate in one-on-one meetings at the 2019 Ladenburg Thalmann Healthcare Conference to be held on September 24, 2019 in New York, NY.

  • Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
    PR Newswire

    Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

    The Phase IIb double-blind, randomized, 90-day dose-ranging trial will assess the primary efficacy endpoint of reduction in HbA1c, as well as safety endpoints. Topline data from the primary cohort of the Phase IIb trial are expected to be released in the fourth quarter of 2019. Oramed Chief Executive Officer Nadav Kidron said, "Our lead oral insulin program could be a major advancement for the diabetes community as we believe it should offer a healthier way to treat diabetes.

  • Oramed to Present at Three Upcoming Conferences
    PR Newswire

    Oramed to Present at Three Upcoming Conferences

    NEW YORK , Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed to Present at World Diabetes Congress
    PR Newswire

    Oramed to Present at World Diabetes Congress

    NEW YORK , July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Announces Xiaoming Gao Joins Board of Directors
    PR Newswire

    Oramed Announces Xiaoming Gao Joins Board of Directors

    Mr. Gao is the Chairman of Hefei Tianhui Incubator of Technologies Co. Ltd. ("HTIT"), which signed a strategic licensing partnership with Oramed in November 2015 to bring oral insulin to China. In 2005, Mr. Gao invested and established Hefei Life Science and Technology Park Investment and Development Co., LTD., and led the existing team to successfully complete the registration of imported Insulin-SciLin in China from 2005 to 2009, and obtained the Imported Drug License.

  • Zacks Small Cap Research

    ORMP: Phase 2b Trial of ORMD-0801 Fully Enrolled; Data Expected 4Q19…

    Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The company is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1), and an oral leptin for the treatment of obesity in patients with T1D.

  • Oramed Provides Clinical Update with Meaningful Data Expected by Year-End
    PR Newswire

    Oramed Provides Clinical Update with Meaningful Data Expected by Year-End

    Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the ...

  • Oramed to Present at BIO International Convention
    PR Newswire

    Oramed to Present at BIO International Convention

    NEW YORK , June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801
    PR Newswire

    Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801

    Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has completed enrollment for its 90-day dose-ranging Phase IIb clinical study of its oral insulin capsule main cohort. Close to 300 patients have now been enrolled. 70% (over 200) of these patients have completed treatment in the study.

  • Zacks Small Cap Research

    ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19…

    Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The company is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1).

  • Oramed to Present at ThinkEquity Conference
    PR Newswire

    Oramed to Present at ThinkEquity Conference

    NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at 3rd Annual Clinical Trials Summit
    PR Newswire

    Oramed to Present at 3rd Annual Clinical Trials Summit

    NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April 29-30, 2019 in Barcelona, Spain. Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will speak about the "Race to Pharmacy", on April 30, 2019. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

  • Oramed Patent Allowed in the U.S. for Oral Exenatide
    PR Newswire

    Oramed Patent Allowed in the U.S. for Oral Exenatide

    NEW YORK , April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed to Present at H.C. Wainwright Global Life Sciences Conference
    PR Newswire

    Oramed to Present at H.C. Wainwright Global Life Sciences Conference

    Dr. Mark Hasleton, Vice President for Business Development of Oramed, will present a corporate overview on April 8, 2019. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology
    PR Newswire

    Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

    Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • PR Newswire

    Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules

    NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801).  The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA", formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China. "We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market," stated Oramed CEO Nadav Kidron.

  • Oramed to Present at BIO CEO & Investor Conference
    PR Newswire

    Oramed to Present at BIO CEO & Investor Conference

    Nadav Kidron, Chief Executive Officer of Oramed, will present a corporate overview on February 12, 2019. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.